| Date | Form | Description | Docs | XBRL | Pages |
| 03/24/21 | 8-K | Current report filing |
|
25 | |
| 03/24/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/23/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/11/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
30 |
| 02/05/21 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
3 | |
| 02/05/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 02/01/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/28/21 | 8-K | Current report filing |
|
2 |
Latest News & Events
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Read More...Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Read More...Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Read More...